Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.71 |
| ▸ | HRH1 | P35367 | 2/20 | 0.71 |
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14372307 | 0.85 | HRH3 (0.50) | HRH3HRH1HTR6HTT | |
| SCHEMBL4915719 | 0.84 | HRH3 (0.52) | HRH3HRH1MLNRCYP2D6 | |
| SCHEMBL4915238 | 0.84 | HRH3 (0.70) | HRH3HRH1NPC1HTTSMN1; SMN2 | |
| SCHEMBL4913619 | 0.84 | HRH3 (0.70) | HRH3HRH1 | |
| Gsk239512 SCHEMBL167578 | 0.83 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL5159251 | 0.83 | HRH3 (1.00) | HRH3HRH1 | |
| Gsk239512 SCHEMBL29360933 | 0.83 | HRH3 (1.00) | HRH3HRH1 | |
| Hydrochloric Acid SCHEMBL5427461 | 0.82 | HRH3 (0.98) | HRH3HRH1 | |
| SCHEMBL4918406 | 0.81 | HRH3 (0.67) | HRH3HRH1NPC1HTTSMN1; SMN2 | |
| SCHEMBL4926431 | 0.81 | HRH3 (0.67) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080380-A1 | Therapeutic Uses | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| EP-2804853-A1 | THERAPEUTIC USES | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013107336-A1 | THERAPEUTIC USES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-07-25 | — | — | WO | disclosed |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| EP-1756094-A1 | 3-CYCLOALKYLBENZAZEPINES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005123723-A1 | 3-CYCLOALKYLBENZAZEPINES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080380-A1 | Therapeutic Uses | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 6/4885MLNR 604/4885 |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885MLNR 962/4885 |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885HRH1 4/4885MLNR 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.